Liminal BioSciences Inc. (NASDAQ:LMNL) (“Liminal BioSciences” or the “Company”), announced that a consolidation of all of the issued and outstanding common shares of the Company (“Common Shares”) on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Share Consolidation”), will become effective at the opening of trading on February 1, 2023 (the “Effective Date”). The Company’s current trading symbol will remain unchanged. The Consolidation was previously approved by the Company’s shareholders at the special meeting of the shareholders held on January 20, 2023.
Liminal BioSciences Announces 1-For-10 Reverse Stock Split
Liminal BioSciences Inc.
Related Posts
SVB Leerink Maintains Market Perform on Cigna, Raises Price Target to $335
SVB Leerink analyst Whit Mayo maintains Cigna (NYSE:CI) with a Market Perform and raises the price target from $305 to $335.
Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating CLN-617, A Novel Fusion Protein Uniquely Harnessing Both IL-2 And IL-12 Cytokines
Cullinan Oncology, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical
C21 Investments Q3 2023 Revenue Declines 9.2% YoY, What About Net Income?
C21 Investments Inc. (OTCQX: CXXIF) (CSE:CXXI) released its interim financial statements for the third quarter ended October 31, 2022, revealing revenue of $7.2 million, an unfavorable decrease of 9.2% compared to $7.9 million in Q3 2021.